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ABSTRACT
The removal of intervening sequences (introns) from a primary RNA transcript is catalyzed by the spliceosome, a large
ribonucleoprotein complex. At the start of each splicing cycle, the spliceosome assembles anew in a sequentially ordered
manner on the pre-mRNA intron to be removed. We describe here the identification of a series of naphthalen-2-yl hydroxamate
compounds that inhibit pre-mRNA splicing in vitro with mid- to high-micromolar values of IC50. These hydroxamates stall
spliceosome assembly at the A complex stage. A structure–activity analysis of lead compounds revealed three pharmacophores
that are essential for splicing inhibition. Specifically, a hydroxamate as a zinc-binding group and a 6-methoxynaphthalene cap
group are both critical, and a linker chain comprising eight to nine methylene groups is also important, for the specific binding
to the docking site of a target protein molecule and precise positioning of the zinc binding group. As we found no correlation
between the inhibition patterns of known histone deacetylases on the one hand and pre-mRNA splicing on the other, we
conclude that these compounds may function through the inhibition of the activities of other, at present, unknown spliceosome-
associated zinc metalloprotein(s).
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INTRODUCTION
The removal of introns from a primary RNA transcript is
catalyzed by a large ribonucleoprotein (RNP) complex termed
the spliceosome. This is a highly complex and dynamic
RNP machine. It is composed of the five snRNPs U1, U2,
U4, U5, and U6 and a large number of non-snRNP proteins
(Wahl et al. 2009). Spliceosomes assemble in a stepwise
manner and thus pass through a series of distinct complexes.
Initially, the U1 and U2 snRNPs bind the pre-mRNA,
forming the A complex. Subsequently, the U4/U6.U5 tri-
snRNP associates, and the precatalytic B complex is generated.
After major rearrangements resulting in the displacement
of U1 and U4, the activated spliceosome (Bact) is formed,
followed by additional restructuring and catalysis of step 1
of splicing. This involves cleavage at the 59 splice site of the
pre-mRNA and the ligation of the 59 end of the intron to
the so-called branch site to form a lariat-like structure. This
leads to formation of the spliceosomal C complex, which
catalyzes step 2 of splicing, during which the intron is
excised and the exons are ligated together to form mRNA.
Subsequently, the spliceosome dissociates, and the snRNPs
are recycled for additional rounds of splicing.
Aberrant pre-mRNA splicing is associated with many
human diseases, including cancer, and neurodegenerative
and autoimmune diseases, making the spliceosome a highly
attractive drug target (Tazi et al. 2005b). Small molecules
arresting spliceosome assembly at defined points would
also be of great use for the detailed investigation of the
structure and function of the spliceosome. To date, only a
limited number of small-molecule inhibitors of pre-mRNA
splicing have been identified. These include antibiotics
(erythromycin, Cl-tetracycline, and streptomycin) (Hertweck
et al. 2002), a biflavanoid (isoginkgetin) (O’Brien et al. 2008),
inhibitors of the kinase activity of topoisomerase I (Pilch
et al. 2001; Tazi et al. 2005a), antitumor drugs targeting the
U2 snRNP—i.e., spliceostatin A (Kaida et al. 2007) and
pladienolide (Kotake et al. 2007)—selected inhibitors of
histone deacetylases and histone acetyltransferases (Kuhn
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2012), and 1,4-naphthoquinones and 1,4-heterocyclic
quinones with known anticancer activity (Berg et al. 2012).
The specific spliceosome targets of these compounds have
been identified in only a few cases. The lack of a clear
understanding of their mechanism of action may be partly
due to the structural complexities of many of these compounds.
Several spliceosome-associated proteins possess potential
enzymatic activities whose function in the splicing reaction
remains unclear (Hartmuth et al. 2002; Rappsilber et al.
2002; Zhou et al. 2002; Jurica and Moore 2003; Deckert
et al. 2006). For example, numerous peptidyl–prolyl isom-
erases have been found, even though it is not clear whether
their isomerase activity is required at all, or whether their
domains are involved in protein–protein interactions. In
addition, many proteins exhibit zinc-binding motifs, sug-
gesting that zinc ions may have functional and/or structural
roles in splicing (Rappsilber et al. 2002; Zhou et al. 2002;
Jurica and Moore 2003; Agafonov et al. 2011). Additionally,
the activity of histone deacetylases (HDACs), which are
classical zinc metalloproteases, has been shown to be impor-
tant for splicing catalysis, although their precise functions in
the splicing process are not clear (Hnilicova´ et al. 2011). In
fact, zinc depletion by the chelator 1,10-phenanthroline
(1,10-phe) has been shown to inhibit the second step of
splicing (Shomron et al. 2002). It has been demonstrated
that specific zinc-chelating agents that perturb the acetyla-
tion state of proteins (through inhibition of HDACs activity)
block the splicing cycle (Kuhn et al. 2009). However, the
exact relationship between zinc chelation, protein acetyla-
tion state, and splicing inhibition is not clear, as only a
limited set of HDAC inhibitors (HDACis) was screened. In
the present work, we sought to clarify this relationship
by screening a HDACi library that was structurally more
diverse (Chen et al. 2008; Canzoneri et al. 2009; Oyelere
et al. 2009; Mwakwari et al. 2010a,b; Patil et al. 2010). We
report here the elucidation of unique molecular features
that confer splicing inhibition upon zinc-chelating agents
with HDAC inhibition activity. Native gel analyses of splicing
reactions revealed that these agents inhibit spliceosome
assembly at an early stage, with the formation/stability even
of the A complex compromised. The absence of any cor-
relation between HDAC and the splicing-inhibition activities
of these compounds suggests that the primary target(s)
involved in splicing inhibition are not HDACs. However,
the existence of certain similarities does suggest possible
structural resemblance(s) in the docking site and a common
involvement of zinc ions.
RESULTS AND DISCUSSION
Screening of structurally diverse HDACis for splicing
inhibition activity
Earlier work has demonstrated the presence of HDACs
in purified populations of spliceosomes (Rappsilber et al.
2002; Zhou et al. 2002; Gunderson et al. 2011), and based
on this information, we previously investigated the splicing
inhibition activity of selected HDAC inhibitors (Kuhn et al.
2009). These HDACis inhibited splicing with sub- to low-
millimolar IC50 values (the concentration giving 50% in-
hibition). However, there was no clear evidence linking the
effects of these compounds on splicing with their actual
inhibition of HDACs, especially as their IC50 values in
splicing were found to be several orders of magnitude higher
than the reported values for HDAC inhibition. HDACs have
18 known isoforms, organized into four different classes.
Classes I, II, and IV depend on a catalytic zinc ion and differ
in their cellular location, while Class III HDACs require
NAD+ (Ropero and Esteller 2007). The prototypic pharma-
cophore for HDACi consists of three distinct structural
motifs: a recognition cap group, a hydrophobic linker, and
a zinc-binding group (Fig. 1; Miller et al. 2003; Mwakwari
et al. 2010b). The recognition cap group moieties of
HDACis interact with amino acid residues on the surface of
HDACs and present excellent opportunities for the selec-
tive modulation of their biological activities (Mwakwari
et al. 2010b). We surmised that profiling the splicing in-
hibition activities of HDACis that differ with respect to
their three distinct structural motifs might help us to discern
possible links between HDAC inhibition and inhibitory
effects on the splicing reaction. To this end, we first screened
a small (63-member), yet structurally diverse HDACi library
(see Supplemental Table S1 for the structures) at 100 mM
using a conventional in vitro splicing assay. The HDAC
inhibition activity of compounds in the screened library
against HDAC1 and HeLa cell nuclear extract HDACs
ranges from single digit- to mid-nanomolar (Chen et al.
2008; Canzoneri et al. 2009; Oyelere et al. 2009; Mwakwari
et al. 2010a; Patil et al. 2010). Despite their potency, these
HDACis did not broadly inhibit splicing. We identified
only two compounds—6-methoxynaphthalen-2-yl hydrox-
amates 24 and 25 that noticeably inhibit splicing at 100 mM
(Fig. 2). The structures of these compounds are almost
identical, differing only in the length of a hydrophobic
linker, six methylene groups for 24 and seven for 25. More
detailed investigation revealed that these compounds in-
hibit pre-mRNA splicing with the same efficiency (Fig. 2B).
Complete inhibition of splicing was observed at 150 mM
FIGURE 1. The prototypic pharmacophore for histone deacetylase
inhibitors (here, SAHA), which typically is comprised of three distinct
structural motifs: a recognition cap group, a hydrophilic linker, and
a zinc-binding group.
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(Fig. 2B, lanes 4,8), with an IC50 value of z130 mM for
both compounds (Table 1).
To determine at which stage splicing complex formation
is inhibited, we performed a splicing time course experi-
ment. The spliceosomal complexes formed were analyzed
by native agarose gel electrophoresis. After 2 min of splicing,
predominantly A and B complexes were visible in the DMSO
control (Fig. 2C, lane 2). After 7 min, most A complexes had
been converted into B complexes, which were, in turn,
converted into later complexes (Bact, C) after 20 min. After
60 min, only small amounts of the A, Bact, and C were still
visible (lanes 3–5). In the presence of 250 mM of com-
pound 24 or 25, the kinetics of splicing complex assembly
appeared similar to each other but differed dramatically
from those in the DMSO control (Fig. 2C, lanes 6–15).
Mainly A complexes accumulated at all of the time points
analyzed. Thus, B complex formation is inhibited, indicat-
ing that one or more protein factors required for it are
inactivated by these compounds. In addition, the amount
of stalled A complexes was significantly lower than in the
DMSO control reaction (cf. the 2-min time point, lane 2).
This indicates that the formation and/or
stability of spliceosomal A complexes is
compromised by these HDACis. These
data imply that potential targets of these
compounds also include proteins in-
volved in the assembly of the A com-
plex. Remarkably, compound 24 has
an HDAC inhibition activity 15 times
higher than that of compound 25 (Table
1; Patil et al. 2010), yet both compounds
stalled spliceosome assembly to approx-
imately the same extent. Another in-
triguing observation is the fact that
compound 9 (Supplemental Table S1),
an analog of 24 with a single methy-
lene chain deletion and a more than
eightfold stronger HDAC inhibition
than 24 (Chen et al. 2008), was not
identified as a splicing inhibitor in the
primary screen. These data, together with
the fact that only two structurally related
compounds have been identified among
the 63 diverse potent HDACis, suggest
that the target(s) of these compounds
responsible for splicing inhibition may
not be HDACs.
Structure–activity relationship
(SAR) of splicing inhibition
The screening of the HDACi library
(Oyelere et al. 2009; Patil et al. 2010)
for splicing inhibition identified
6-methoxynaphthalen-2-yl hydroxamates
24 and 25 as small molecules that inhibit spliceosome
assembly at an early stage, to about the same extent, with
IC50 values close to 130 mM (Table 1). These data provided
an initial indication that the inhibition of splicing may not
be due to the targeting of HDACs. To investigate this
question further, we carried out a detailed structure–activity
analysis of these compounds. We synthesized a series of
structural analogs of compounds 24 and 25 and tested their
effect on the in vitro splicing of 32P-labeled MINX pre-
mRNA, as well as their HDAC inhibitory activity against
representative class I and class II HDAC isoforms—HDAC1,
HDAC6, and HDAC8. First, we investigated the length of
a hydrophobic linker between the recognition cap and
zinc-binding groups. Compounds 24 and 25 have 6- and
7-methylene chain linkers, respectively (Table 1). A shorter
version present in the initial compound collection, with
five methylene groups, was filtered out as inactive against
splicing (compound 9) (Supplemental Table S1). We thus
experimented with introducing longer linkers. Indeed,
single- (compound 67a), as well as double- (compound
67b) methylene chain extensions significantly increased
FIGURE 2. Hit compounds 24 and 25 inhibit pre-mRNA splicing in vitro and lead to an
accumulation of spliceosome assembly intermediates. (A) Structures of the compounds. (B)
Increasing concentrations of compounds 24 and 25 were tested for their effect on the splicing
of 32P-labeled MINX pre-mRNA. After splicing, the radiolabeled RNA was analyzed by
denaturing PAGE followed by autoradiography. The left-most lane shows the DMSO control
experiment. Compound numbers are shown at the top of the panel, and drug concentrations
tested are shown immediately below the compound numbers. The positions of lariat-intron,
pre-mRNA, fully spliced mRNA, and 59 exon (top to bottom) are indicated on the left. (C)
Formation of splicing complex on 32P-labeled MINX pre-mRNA in the presence of 250 mM of
the respective compounds. Reactions were stopped at the time points indicated, and the
products were analyzed on a native agarose gel. Bands were visualized by phosphor imaging.
The positions of the splicing complexes (H, A, and B) are indicated.
Zinc chelating spliceosome inhibitors
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splicing inhibition potency (Table 1).
Further increase in the length resulted
in compounds that were less active (i.e.,
67c) or slightly less potent (i.e., 67d),
although these were still almost as po-
tent as the lead compounds 24 and 25.
Thus, there is a correlation between the
anti-splicing activity and the length of
the linker, with .an optimum number of
methylene groups of eight and nine. As
for the HDAC inhibitory activity, com-
pounds 67a and 67b inhibited HDAC1
and HDAC6 with mid-nanomolar IC50s
and were completely inactive against
HDAC8, while 67c potently inhibited
HDAC6 and HDAC8 and was almost
inactive against HDAC1. Interestingly,
compound 67d had the poorest HDAC
inhibitory activity; it was found to be
inactive against HDAC1 and HDAC6
and weakly active against HDAC8, yet it
showed significant inhibition of splicing.
Another structural motif of the phar-
macophore that we investigated was the
naphthalene cap group. The substitution
of the 6-methoxy moiety by a protic
electron-donating group such as OH or
NH2 was detrimental to the function of
the compounds, as these changes abol-
ished splicing inhibitory activity (Table 1;
cf. 70b,70c and 24; 70d and 25). In
contrast, compounds 70b, 70c, and 70d
were found to be broadly active against
the HDAC isoforms tested, with single-
digit nanomolar to mid-nanomolar IC50s
against HDAC1 and HDAC6. The ob-
servation that there is no correlation
between anti-HDAC and anti-splicing
activities of these molecules supports
the suggestion that the targets of these
compounds in splicing are not HDACs.
In addition, these data suggest that the
naphthalene cap group needs to be spe-
cifically recognized by the target pro-
tein(s). It is noteworthy that compounds
74a and 74b—containing a single meth-
ylene extension of the naphthalene cap
6-ether moiety compared with 25 and
67b, respectively— possess almost the
same splicing inhibitory activity as the
initial compounds.
To investigate the role of zinc che-
lation in the splicing-inhibitory activity
of these naphthalene-2-yl hydroxamates,
we synthesized methyl esters 80 and 81
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and carboxamide 82. These compounds
are the derivatives of the hydroxamates
24 and 67b. As expected, all of these
nonhydroxamate analogs lacked HDAC
inhibitory activity. Significantly, they
also failed to inhibit splicing in vitro
(Table 1). These results indicate that zinc
coordination is important for both anti-
HDAC and anti-splicing activities. An
add-back experiment was performed to
test whether the inhibition is, indeed, due
to the chelation of zinc (Fig. 3). The
indicated concentrations of ZnCl2 were
added at the beginning of the splicing
reaction (addition time 0 min, odd lanes)
or after 1 h incubation (addition time
60 min, even lanes), followed by another
60-min incubation under splicing con-
ditions. The addition of 30 and 100 mM
ZnCl2 to the control reaction with DMSO
had little effect on splicing, although the
pre-mRNA substrate appeared to be
slightly stabilized in some cases (lanes
1–6). The splicing reaction was sub-
stantially inhibited in the presence of
100 mM 67b, one of the most potent
compounds described here (lanes 7,8).
Addition of 30 mM ZnCl2 before initi-
ation of the splicing reaction did not
reverse inhibition by 67b, whereas ad-
dition of 100 mM ZnCl2 restored splic-
ing efficiency to near control levels
(lanes 9,11). Addition of 100 mM ZnCl2
also led to a general increase in the
amount of the splicing substrate, but
the observed increase in the splicing
products is not due solely to this ap-
parent stabilization effect. Interestingly,
addition of ZnCl2 to the inhibited splic-
ing reaction 1 h later had no effect (lanes
10,12). These data suggest that com-
pound 67b irreversibly inhibits splic-
ing; once it binds to its target protein
and chelates its zinc ion, the inhibitory
effect, which could potentially involve a
structural change in the targeted protein,
can no longer be reversed by exoge-
neously added zinc ions. In contrast,
allowing compound 67b to bind zinc
prior to interacting with its target protein
neutralizes its inhibitory effect, presum-
ably by preventing 67b from removing
the zinc that is normally bound by its
target protein. This result confirms the
principal role of zinc chelation in the
TABLE 1. Continued
(NT) not tested, (NI) no significant inhibition (below 20%). % HDAC inhibition activities of
the compounds at 10 mM are shown if the IC50 was above 10 mM.
aCited from references (Chen et al. 2008; Patil et al. 2010)—activities against HeLa nuclear
extract (HDAC 1 and 2).
Zinc chelating spliceosome inhibitors
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mechanism of action of the compounds described. However,
one should note the dramatic difference between the effects
observed here, and those of the zinc chelation by 1,10-phe,
which requires millimolar concentrations and results in the
reversible inhibition of step 2 of splicing (Table 1; Shomron
et al. 2002).
CONCLUSIONS
All three structural motifs of the pharmacophore for HDACis
exhibit a synergistic activity, as the cap group and linker are
both important for the specific binding to the docking site
of the target protein molecule and precise positioning of
the zinc-binding group for effective zinc chelation. The
SAR analysis of the compounds identified that inhibit splicing
reveals that all three groups are important for splicing
inhibition activity, though to different degrees. The intact
zinc-binding group is absolutely essential, and the naph-
thalene cap group is also important; the hydrophobic linker
has a more pronounced length restriction in that linkers
with eight and nine methylene groups confer the highest
activity upon the compounds. Taken together, our data
suggest that splicing inhibition involves not only the in-
teraction of the inhibitor with one or more splicing factors
but also that its zinc binding group is positioned close to the
zinc binding group of the target protein, leading to chelation
of its zinc. They furthermore suggest that the target proteins
are not HDACs. In fact, there are a number of spliceosomal
proteins that contain zinc finger motifs and associate with
different complexes during the spliceosome assembly
pathway (Rappsilber et al. 2002; Zhou et al. 2002; Jurica
and Moore 2003; Bessonov et al. 2008, 2010; Agafonov
et al. 2011). Their detailed biochemical function is not yet
clear, and they could well be targets of the compounds
presented here. Our future work will include the affinity
labeling of these compounds which, it is hoped, will aid
the identification of the target(s) in the spliceosome and




In vitro HDAC inhibition was assayed using the HDAC Fluori-
metric Assay/Drug Discovery Kit as previously described (Chen
et al. 2008; Oyelere et al. 2009; Mwakwari et al. 2010a). Briefly,
15 mL of HeLa nuclear extract was mixed with 5 mL of 103
compound and 5 mL of assay buffer. Fluorogenic substrate (25 mL)
was added, and the reaction was allowed to proceed for 15 min
at room temperature and then stopped by addition of a devel-
oper containing TSA. Fluorescence was monitored after 15 min
at excitation and emission wavelengths of 360 and 460 nm,
respectively. IC50 values were determined using logit plots. Assays
of HDAC1, HDAC6, and HDAC8 activity were performed accord-
ing to the manufacturer’s instructions.
Splicing substrates, reactions, and spliceosome
complex analysis
Uniformly 32P-labeled, m7G(59)ppp(59)G-capped MINX pre-
mRNA was synthesized in vitro by T7 runoff transcription.
Splicing reactions contained 30% (v/v) HeLa nuclear extract in
buffer D (20 mM HEPES-KOH at pH 7.9, 100 mM KCl, 1.5 mM
MgCl2, 0.2 mM EDTA, 20% [v/v] glycerol, 0.5 mM DTT, 0.5 mM
PMSF), 25 mM KCl, 3 mM MgCl2, 20 mM creatine phosphate,
2 mM ATP, 3 nM 32P-labeled pre-mRNA, 2.5% (v/v) DMSO, and
the indicated concentration of the chemicals tested for their effect
on splicing. For the analysis of the splicing products, the reactions
were stopped after a 60-min incubation at 30°C. RNA was isolated
by proteinase K treatment, phenol extraction, and ethanol
precipitation, and then separated by denaturing polyacrylamide
gel electrophoresis on a 7 M urea, 14% (w/v) polyacrylamide
gel and visualized by phosphor imaging (Typhoon 8600, GE
Healthcare). For the analysis of spliceosomal complexes, 10 mL
of the splicing reaction were added to 2.5 mL of loading buffer
(13 TBE, 30% [v/v] glycerol, 1.25 mg/mL heparin) at the time
points indicated, and the mixture was then placed on ice. Complexes
were separated on 1.5% (w/v) agarose gels and visualized by
phosphor imaging.
SUPPLEMENTAL MATERIAL
Supplemental material is available for this article.
FIGURE 3. Relieving the inhibitory effect of the compound 67b.
Radiolabeled MINX pre-mRNA was incubated in nuclear extract
under standard splicing conditions in the presence of DMSO (lanes 1–6)
or compound 67b (lanes 7–12) at the semi-inhibitory concentration
of 100 mM, and the indicated concentration of ZnCl2 that was added
at the indicated reaction time points. After splicing, the radiolabeled
RNA was analyzed by denaturing PAGE followed by autoradiography.
The positions of lariat-intron, pre-mRNA, and fully spliced mRNA
(top to bottom) are indicated on the left.
Patil et al.
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